Zorifertinib With Osimertinib for NSCLC With Meningeal Progression

This is a clinical trial that aims to test Zorifertinib when used together with a known drug, Osimertinib. The goal is to learn if this combination is safe and works for people with advanced Non-Small Cell Lung Cancer (NSCLC) whose cancer has spread to the membranes surrounding the brain and spinal cord (a condition called leptomeningeal metastases) after being treated with Osimertinib.

Trial Details

NCT ID
NCT07361705
Phase
PHASE1
Sponsor
Alpha Biopharma (Jiangsu) Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Zorifertinib and Osimertinib Combination Therapy
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Shengyang, City, China|36.2001,104.546
  • Guangzhou, Province, China|23.11667,113.25
  • Henan, Province, China|37.92189,112.22494
  • Shanxi, Province, China|27.66628,120.0505

Key Eligibility Criteria

  • For inclusion in the study, patients must meet all of the following criteria.
  • The patient or the guardian is required to understand and sign the informed consent form of this study.
  • During the screening period, subjects must have a previous histological or cytological diagnosis of NSCLC with a sensitising EGFR mutation (includi…
  • Only patients who have developed meningeal progression after osimertinib treatment (at a standard dose of 80 mg QD; if the dose is 160 mg QD, it mu…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →